Connect your AI

Microbot Medical MBOT Payments to Acquire Marketable Securities

Payments to Acquire Marketable Securities at other companies

Intuitive SurgicalISRG

——

Other financials

Income statement

Revenue$105.0K—

Gross profit$2.0K—

Operating income-$4.3M-43.0%

Net income-$3.7M-41.1%

EPS (diluted)-$0.05+37.5%

Balance sheet

Cash & equivalents$3.7M+13.7%

Total debt$898.0K+551%

Total equity$74.1M+156%

Total assets$78.1M+153%

Cash flow

Operating cash flow-$5.1M-75.8%

CapEx$108.0K+731%

Free cash flow-$5.2M-78.8%

Valuation

Market cap$128.28M+36.1%

Enterprise value$125.53M+39.0%

P/S674.3×—

Profitability

Operating margin25,292.9%—

Net margin-3,669.9%—

FCF margin-852.8%—

Returns & leverage

Return on equity-27.6%-10.2pp

Debt / equity0×0.0×

Current ratio22.6×+6.4×

Where this comes from

Reported directly by Microbot Medical in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireMarketableSecurities.

The official record: Microbot Medical’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Microbot Medical's payments to acquire marketable securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Microbot Medical's payments to acquire marketable securities?: Microbot Medical (MBOT) reported payments to acquire marketable securities of $441K in Q1 2026.
How has Microbot Medical's payments to acquire marketable securities changed year-over-year?: Microbot Medical's payments to acquire marketable securities decreased by 98.4% year-over-year, from $28.12M to $441K.